Consume Product

I really wish they would give sources for these juicy greentexts because it would force them to improve the quality. (don't sAuCe me, if we're going to share these they should be correct)

Axovant is a biotech company that Vivjeet founded. The Alzheimers drug was called RVT-101 originally developed by GlaxoSmithKline under the name SB-742457.

If [BioSpace](https://www.biospace.com/why-former-medivation-ceo-and-a-once-failed-alzheimer-s-drug-could-be-a-recipe-for-disaster-for-axovant) is to be believed, GSK was willing to give up the drug for $5 million because it had already failed ***four consecutive*** mid-stage trials not just two.

Also, it wasn't just his mother, but his brother who were both VP's within Axovant and were given a combined 1,012,500 shares.